Read for the rise of A-shares!
Tsinghua University, the name is deafening both in the academic world and in the industrial investment community in the market.
According to statistics, Tsinghua University once directly or indirectly controlled 89 listed companies, and it was also the largest university listed company "Tiantuan".
We have listed a few here, and we can see that such as Mindray Medical, Meituan, Weir, etc. are all leaders in their respective industries, and their market capitalization is also very large.
Of course, the common denominator of these above-mentioned enterprises is that in addition to the core personnel have a Tsinghua education background and the company is the head of the industry, they have also made outstanding contributions to the domestic market of the industry.
And on August 28, another Tsinghua "Pangu in the industry" was coming to A-shares.
Recently, Pinchi Medical has completed the registration of listing counseling in relevant departments, and the counseling company is CICC.
According to the counseling work arrangement, it is expected that the "Pangu in the industry" will be able to start the IPO journey by the end of this year.
In recent years, more and more companies have chosen to go public in Hong Kong, and there are not a few companies listed in AH and Hong Kong at the same time, and the companies that choose "hard" big A are either not in a hurry to go public, or they have absolute confidence in themselves.
Pinchi Medical is obviously the one with absolute self-confidence.
First of all, Pinchi's "background is very hard".
Pinchi Medical's "Tsinghua Department" is not the same as the "Tsinghua Department" of Mindray Medical and Weir Shares.
Pinchi's R&D team is not only all "good seedlings" from Tsinghua University, but the company's chief scientist is the current president of Tsinghua University - Li Luming.
In 2000, in the discipline exchange between Tsinghua University and Beijing Tiantan Hospital, Academician Wang Zhongzhong proposed to study brain pacemakers with significant clinical, economic and scientific value.
Li Luming's long-standing interest in medical research was instantly ignited.
He has always wanted to do scientific research that can effectively solve the problem of human needs, and since the physical condition of his relatives is not very good, there is no reason not to challenge.
18 years later, this aerospace medical professor who "wants to leave something tangible in the academic world" gathered all "academic bigwigs" and platforms from all parties to really make the pacemaker of his dreams, and also won the first prize of the National Science and Technology Award.
Secondly, the core technology ranks first in the country.
Everyone should be familiar with the problem of hand tremors in the elderly. The severity of this disease is likely to develop into Parkinson's, and the number of people suffering from Parkinson's disease in mainland China has reached 2.5 million.
For this incurable disease, Pinchi Medical has given a solution, that is, the "Tsinghua brand" brain pacemaker.
At present, 17 of the medical devices that have been approved by the relevant departments in mainland China are related to neuromodulation, and 14 of them are produced by Pinchi Medical, accounting for 82.35%.
Moreover, Pinchi Medical's technology is not false at all, all of them are really usable.
Parkinson's patients who are equipped with Pinchi Medical Brain Pacemaker can immediately stop tremor as long as they turn on the remote control switch, walk like a normal person, and do not need to take medication for a long time after that.
It not only achieves "medicine to cure the disease", but also greatly saves the economic expenses of the patient's family.
According to statistics, Pinchi Medical's brain pacemaker has been implanted 12,000 times in nearly 200 hospitals across the country, saving an average of 100,000 yuan a year for each family, and saving a total of 400 million yuan in the past three years.
For the follow-up patient return cost, Pinchi Medical has established a remote program control system.
In the local hospital, patients can establish audio, video and data links with remote attending doctors through Internet technology to achieve remote program control, which can reduce the economic burden of postoperative return by more than 90%.
Such a skilled and practical team is precisely the favorite of the capital circle.
Pinchi Medical is in the field of neuromodulation is very favored by investment institutions, and even in the cold winter of the investment circle in 2022, this track has still been invested 10 times, bucking the trend.
There are two main reasons for preference.
One, there is a wide range of downstream applications.
The nervous system governs all vital organs of the human body, so neuromodulation technology has a wide range of applications, including neurological injury, epilepsy, audio-visual and auditory impairment, and peripheral vascular diseases.
The other is that the competition on the track is not fierce.
At present, there are only about 17 companies in the field of neuromodulation in mainland China and only about 18 companies overseas, and most of these companies are focused on pain suppression.
Only Pinchi Medical and Jingyu Medical have bypassed the traditional field to carry out innovation, so these two companies are very popular with capital in the venture capital circle.
Take Pinchi Medical as an example, two of the top three active investment institutions in the pharmaceutical industry last year invested in Pinchi Medical.
It's not just institutions like Legend Capital that focus on medicine like Pinchi, but we can also see star investment institutions such as Hillhouse Capital, China Life Investment, and Greater Bay Area Common Home Development Fund in the seven rounds of financing of Pinchi Medical.
Even in 2011, the Beijing Municipal Science and Technology Commission injected 10 million yuan of scientific research funds into Pinchi Medical in the form of government equity investment, which helped the company breathe a big sigh of relief.
Therefore, on the whole, there are major star institutions behind Pinchi Medical, and there is no shortage of funds. This is very beneficial to the company's subsequent technological growth and IPO progress.
To sum it up.
Pinchi Medical has recently completed the listing counseling and filing in relevant departments, and is about to start its IPO journey in the A-share market, which is also another "Tsinghua-based" listed company since Mindray Medical.
Pinchi Medical's technology is not only the only one in China, but also a rare technology that truly considers patients, leading China's implantable medical devices to complete the transformation from 0 to 1.
The above analysis does not constitute specific trading advice, the stock market is risky, and investment should be cautious.
Follow Feijing Investment Research (id: Feijingtouyan) and receive the most valuable "Growth 20: 20 Companies with the Most Growth Potential in 2024" investment report now!
Source: Flying Whale Investment Research